Jena French on Combinations With Immunotherapy in Thyroid Cancer

Jena D. French, PhD
Published: Monday, Feb 06, 2017



Jena D. French, PhD, instructor of Medicine, Division of Endocrinology, Metabolism and Diabetes, University of Colorado Denver, discusses combination regimens exploring immunotherapy and lenvatinib (Lenvima) as treatment for patients with thyroid cancer.

Targeting PD-1 with monotherapy has been successful in several tumor types, French explains. However, it does not produce a complete response throughout an entire patient population. Additionally, lenvatinib has been shown to demonstrate good partial responses in patients; therefore, PD-1 antibodies and lenvatinib combined could show promising efficacy levels.

French says that combination therapies will become a bigger focus in the future treatment landscape of thyroid cancer.


Jena D. French, PhD, instructor of Medicine, Division of Endocrinology, Metabolism and Diabetes, University of Colorado Denver, discusses combination regimens exploring immunotherapy and lenvatinib (Lenvima) as treatment for patients with thyroid cancer.

Targeting PD-1 with monotherapy has been successful in several tumor types, French explains. However, it does not produce a complete response throughout an entire patient population. Additionally, lenvatinib has been shown to demonstrate good partial responses in patients; therefore, PD-1 antibodies and lenvatinib combined could show promising efficacy levels.

French says that combination therapies will become a bigger focus in the future treatment landscape of thyroid cancer.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Publication Bottom Border
Border Publication
x